WESTLAKE VILLAGE, Calif., Sept. 15, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 39,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were…Read More
Arcutis Biotherapeutics Inc Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4
